Yves A. DeClerck

12.5k total citations
127 papers, 9.1k citations indexed

About

Yves A. DeClerck is a scholar working on Cancer Research, Oncology and Molecular Biology. According to data from OpenAlex, Yves A. DeClerck has authored 127 papers receiving a total of 9.1k indexed citations (citations by other indexed papers that have themselves been cited), including 73 papers in Cancer Research, 55 papers in Oncology and 53 papers in Molecular Biology. Recurrent topics in Yves A. DeClerck's work include Protease and Inhibitor Mechanisms (53 papers), Neuroblastoma Research and Treatments (34 papers) and Peptidase Inhibition and Analysis (25 papers). Yves A. DeClerck is often cited by papers focused on Protease and Inhibitor Mechanisms (53 papers), Neuroblastoma Research and Treatments (34 papers) and Peptidase Inhibition and Analysis (25 papers). Yves A. DeClerck collaborates with scholars based in United States, Belgium and Japan. Yves A. DeClerck's co-authors include Hiroyuki Shimada, Laurence Blavier, Tasnim Ara, Walter E. Laug, Scott A. Bergfeld, Fang Hua, Robert C. Seeger, Suzan Imren, K E Langley and Peter A. Jones and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Yves A. DeClerck

127 papers receiving 8.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yves A. DeClerck United States	55	4.3k	4.1k	3.7k	1.5k	1.2k	127	9.1k
Jasti S. Rao United States	54	3.8k 0.9×	2.4k 0.6×	4.4k 1.2×	641 0.4×	1.2k 1.0×	169	8.3k
Evelyn Flynn United States	36	3.1k 0.7×	2.5k 0.6×	6.8k 1.9×	864 0.6×	1.1k 0.9×	66	11.4k
Herbert A. Weich Germany	52	2.9k 0.7×	3.2k 0.8×	7.7k 2.1×	1.1k 0.8×	847 0.7×	114	11.9k
Reuven Reich Israel	59	3.4k 0.8×	3.0k 0.7×	5.4k 1.5×	1.8k 1.2×	1.4k 1.2×	202	11.2k
Jocelyn Holash United States	34	3.0k 0.7×	2.7k 0.7×	8.1k 2.2×	840 0.6×	633 0.5×	46	11.9k
Wun-Jing Kuang United States	12	1.9k 0.5×	2.5k 0.6×	5.8k 1.6×	2.0k 1.3×	979 0.8×	12	11.7k
J Folkman United States	21	3.0k 0.7×	2.6k 0.6×	6.2k 1.7×	717 0.5×	925 0.8×	30	10.3k
Paolo Mignatti United States	40	3.7k 0.9×	2.1k 0.5×	4.5k 1.2×	754 0.5×	1.4k 1.2×	98	8.9k
Stanley Zucker United States	55	4.8k 1.1×	4.2k 1.0×	4.2k 1.1×	1.2k 0.8×	1.1k 0.9×	161	9.6k
Rafael Fridman United States	55	4.4k 1.0×	3.6k 0.9×	3.4k 0.9×	662 0.4×	1.6k 1.3×	109	8.3k

Countries citing papers authored by Yves A. DeClerck

Since Specialization

Citations

This map shows the geographic impact of Yves A. DeClerck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yves A. DeClerck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yves A. DeClerck more than expected).

Fields of papers citing papers by Yves A. DeClerck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yves A. DeClerck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yves A. DeClerck. The network helps show where Yves A. DeClerck may publish in the future.

Co-authorship network of co-authors of Yves A. DeClerck

This figure shows the co-authorship network connecting the top 25 collaborators of Yves A. DeClerck. A scholar is included among the top collaborators of Yves A. DeClerck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yves A. DeClerck. Yves A. DeClerck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Blavier, Laurence, Rebekah Kennedy, G. Esteban Fernández, et al.. (2024). Nuclear factor-κB activation by transforming growth factor-β1 drives tumour microenvironment-mediated drug resistance in neuroblastoma. British Journal of Cancer. 131(1). 90–100. 7 indexed citations

Blavier, Laurence, Rie Nakata, Paolo Neviani, et al.. (2023). The capture of extracellular vesicles endogenously released by xenotransplanted tumours induces an inflammatory reaction in the premetastatic niche. Journal of Extracellular Vesicles. 12(5). e12326–e12326. 23 indexed citations

Wu, Hongwei, Michael A. Sheard, Jemily Malvar, et al.. (2019). Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells. Clinical Cancer Research. 25(15). 4761–4774. 57 indexed citations

Borriello, Lucia, Rie Nakata, Michael A. Sheard, et al.. (2017). Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells. Cancer Research. 77(18). 5142–5157. 146 indexed citations

Lifshitz, Veronica, Saul J. Priceman, Wenzhao Li, et al.. (2017). Sphingosine-1-Phosphate Receptor-1 Promotes Environment-Mediated and Acquired Chemoresistance. Molecular Cancer Therapeutics. 16(11). 2516–2527. 19 indexed citations

Solari, Valeria, Lucia Borriello, Gianluca Turcatel, et al.. (2014). MYCN-Dependent Expression of Sulfatase-2 Regulates Neuroblastoma Cell Survival. Cancer Research. 74(21). 5999–6009. 9 indexed citations

Bergfeld, Scott A., Laurence Blavier, & Yves A. DeClerck. (2014). Bone Marrow–Derived Mesenchymal Stromal Cells Promote Survival and Drug Resistance in Tumor Cells. Molecular Cancer Therapeutics. 13(4). 962–975. 54 indexed citations

Ara, Tasnim, Rie Nakata, Michael A. Sheard, et al.. (2013). Critical Role of STAT3 in IL-6–Mediated Drug Resistance in Human Neuroblastoma. Cancer Research. 73(13). 3852–3864. 105 indexed citations

Silverman, Ayaka M., Rie Nakata, Hiroyuki Shimada, Richard Sposto, & Yves A. DeClerck. (2012). A Galectin-3–Dependent Pathway Upregulates Interleukin-6 in the Microenvironment of Human Neuroblastoma. Cancer Research. 72(9). 2228–2238. 73 indexed citations

10.

Fang, Hua, et al.. (2011). Synergistic Activity of Fenretinide and the Bcl-2 Family Protein Inhibitor ABT-737 against Human Neuroblastoma. Clinical Cancer Research. 17(22). 7093–7104. 31 indexed citations

11.

Ara, Tasnim, Liping Song, Hiroyuki Shimada, et al.. (2008). Interleukin-6 in the Bone Marrow Microenvironment Promotes the Growth and Survival of Neuroblastoma Cells. Cancer Research. 69(1). 329–337. 145 indexed citations

12.

Shimada, Hiroyuki, et al.. (2008). Identification of Galectin-3-binding Protein as a Factor Secreted by Tumor Cells That Stimulates Interleukin-6 Expression in the Bone Marrow Stroma. Journal of Biological Chemistry. 283(27). 18573–18581. 61 indexed citations

13.

Peng, Hongjun, Yasuyoshi Sohara, Rex Moats, et al.. (2007). The Activity of Zoledronic Acid on Neuroblastoma Bone Metastasis Involves Inhibition of Osteoclasts and Tumor Cell Survival and Proliferation. Cancer Research. 67(19). 9346–9355. 41 indexed citations

14.

Song, Liping, Tasnim Ara, Zhongbin Deng, et al.. (2007). The role of paracrine IL-6 and IL-10 in neuroblastoma progression (49.9). The Journal of Immunology. 178(1_Supplement). S84–S84. 1 indexed citations

15.

Badiola, Iker, Yves A. DeClerck, Steven J. Wall, Fernando Vidal‐Vanaclocha, & Elvira Olaso. (2006). The role of DDR1 and DDR2 collagen receptors in tumor progression. Cancer Research. 66. 394–394. 1 indexed citations

16.

Tóth, Márta, M. Margarida Bernardo, David C. Gervasi, et al.. (2000). Tissue Inhibitor of Metalloproteinase (TIMP)-2 Acts Synergistically with Synthetic Matrix Metalloproteinase (MMP) Inhibitors but Not with TIMP-4 to Enhance the (Membrane Type 1)-MMP-dependent Activation of Pro-MMP-2. Journal of Biological Chemistry. 275(52). 41415–41423. 121 indexed citations

17.

Blavier, Laurence & Yves A. DeClerck. (1997). Tissue inhibitor of metalloproteinases-2 is expressed in the interstitial matrix in adult mouse organs and during embryonic development.. Molecular Biology of the Cell. 8(8). 1513–1527. 47 indexed citations

18.

Luo, Michelle P., Brigitte N. Gomperts, Suzan Imren, et al.. (1997). Establishment of Long-Termin VitroCultures of Human Ovarian Cystadenomas and LMP Tumors and Examination of Their Spectrum of Expression of Matrix-Degrading Proteinases. Gynecologic Oncology. 67(3). 277–284. 21 indexed citations

19.

Imren, Suzan, Donald B. Kohn, Hiroyuki Shimada, Laurence Blavier, & Yves A. DeClerck. (1996). Overexpression of tissue inhibitor of metalloproteinases-2 retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion.. PubMed. 56(13). 2891–5. 115 indexed citations

20.

Álvarez, Ofelia, David F. Carmichael, & Yves A. DeClerck. (1990). Inhibition of Collagenolytic Activity and Metastasis of Tumor Cells by a Recombinant Human Tissue Inhibitor of Metalloproteinases. JNCI Journal of the National Cancer Institute. 82(7). 589–595. 197 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact